MRKR
Marker Therapeutics Inc

4,960
Loading...
Loading...
News
all
press releases
Marker Therapeutics (NASDAQ:MRKR) Shares Down 2.7%
Marker Therapeutics, Inc. (NASDAQ:MRKR - Get Free Report)'s share price traded down 2.7% on Friday . The company traded as low as $4.66 and last traded at $4.75. 31,276 shares traded hands during...
Zolmax·1y ago
News Placeholder
More News
News Placeholder
Marker Therapeutics Advances in Immuno-Oncology
Marker Therapeutics (MRKR) has released an update. Marker Therapeutics has announced significant strides in its immuno-oncology programs, including...
TipRanks Financial Blog·1y ago
News Placeholder
Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results
Lead program in patients with lymphoma demonstrated preliminary safety and efficacy results with sustained complete response in first study participant treated with MT-601 (Neldaleucel) following CAR...
Globe Newswire·1y ago
News Placeholder
Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
HOUSTON, March 22, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies...
Globe Newswire·1y ago
News Placeholder
Marker Therapeutics Ends Stock Sale Deal with LPC
An announcement from Marker Therapeutics Inc (MRKR) is now available. Marker Therapeutics, Inc. has terminated its stock sale agreement with Lincol...
TipRanks Financial Blog·2y ago
News Placeholder
Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for Neldaleucel as Nonproprietary Name for MT-601
HOUSTON, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for...
Globe Newswire·2y ago
News Placeholder
Marker Therapeutics (NASDAQ:MRKR) Shares Up 0.4%
Marker Therapeutics, Inc. (NASDAQ:MRKR Get Free Report)s stock price shot up 0.4% on Tuesday . The company traded as high as $5.00 and last traded at $4.96. 28,057 shares were traded...
Zolmax·2y ago
News Placeholder
Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization
Strategic prioritization of clinical programs with focus on MT-601 in patients with lymphoma MultiTAA-specific T cell therapies demonstrate clinical safety and positive clinical data across multiple...
Globe Newswire·2y ago
News Placeholder
Cancer Cell Therapy Focused Marker Therapeutics Announces Pipeline Prioritization
Marker Therapeutics Inc (NASDAQ: MRKR) announced it is restructuring its clinical programs and strategic prioritization of its multi-tumor associated antigen (multiTAA)-specific T cell product...
Benzinga·2y ago

Latest MRKR News

View

Advertisement. Remove ads.

Advertisement. Remove ads.